Advancing CML Management Towards an Ideal Patient Journey
The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
EP: 1.Understanding CML: Your Journey from Diagnosis to Treatment
EP: 2.Navigating CML: Tools to Empower Patients and Caregivers
EP: 3.Empowering CML Caregivers: Strategies and Support Systems
EP: 4.Starting CML Treatment: Collaborative Choices for Better Outcomes
EP: 5.Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
EP: 6.When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
EP: 7.CML Treatment: Scenarios that Necessitate Switching Therapy
EP: 8.Ensuring Informed CML Care from Diagnosis Onward
Now Viewing
EP: 9.Advancing CML Management Towards an Ideal Patient Journey
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- What are the biggest unmet needs you see for CML patients today, and how do you think emerging therapies and research could address those gaps in the future?
- What excites you most about the potential advancements in CML management that may be on the horizon in the next 5-10 years?
- How do you envision the CML patient experience being transformed compared to today?
Recent Videos
Related Content
Acalabrutinib Plus Venetoclax Offers PFS Advantage Over Standard Therapy in Frontline CLL
July 29th 2024Article
A fixed-duration treatment combining acalabrutinib and venetoclax, with or without obinutuzumab, significantly extended progression-free survival in patients with previously untreated chronic lymphocytic leukemia.
